What is the cornerstone therapy for controlling chronic asthma during pregnancy?

Inhaled corticosteroids are recognized as the cornerstone therapy for controlling chronic asthma during pregnancy because they effectively reduce inflammation in the airways, leading to improved asthma control and reduced risk of exacerbations. Their mechanism of action involves modulating the immune response and decreasing airway hyperreactivity, which is essential for managing asthma in pregnant patients.

The use of inhaled corticosteroids is supported by multiple guidelines, which emphasize their safety during pregnancy and their ability to manage chronic asthma symptoms effectively. They provide targeted treatment directly to the lungs, minimizing systemic exposure and potential risks to the developing fetus, making them preferable over other options.

Other treatments, such as mast cell stabilizers, short-acting beta2 agonists, and leukotriene receptor antagonists, may have roles in asthma management but are not considered the primary therapy during pregnancy. While short-acting beta2 agonists are generally used for quick relief of symptoms, they do not address the underlying inflammation and are not sufficient as a long-term controller. Mast cell stabilizers and leukotriene receptor antagonists may have limited use depending on individual patient circumstances but do not hold the same established position as inhaled corticosteroids in current guidelines for pregnant patients with chronic asthma.